Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNanoco Regulatory News (NANO)

Share Price Information for Nanoco (NANO)

Share Price is delayed by 15 minutes
Get Live Data
2.59    -0.31 (-10.69%)
Bid:
2.60
Ask:
2.91
Spread: 0.31 (11.923%)
Market Cap: £4.73m
NANO Live PriceLast checked at - London Stock Exchange

Intraday Nanoco Share Chart

Joint Development Agreement

12 Aug 2011 07:00

RNS Number : 2357M
Nanoco Group PLC
12 August 2011
 



For immediate release

12 August 2011

 

 

NANOCO GROUP PLC

("Nanoco" or "the Company")

 

Joint Development Agreement

 

Nanoco Group plc (AIM: NANO), a world leader in the development and manufacture of cadmium-free quantum dots, announces that it has signed a joint development agreement with one of the world's largest lighting companies which is already a major producer of light emitting diode (LED) lights.

 

The objective of the development agreement is to incorporate Nanoco's cadmium-free quantum dots (CFQDTM) into the lighting company's LEDs to create LED lighting with superior performance characteristics.

 

LED lighting has many advantages over traditional lighting - including long service life, reduced power consumption, compact size and shock resistance - but its colour performance is one factor that has limited its adoption. Nanoco's quantum dots have been shown to overcome this limitation, opening up the possibility of the widespread use of LED lighting in commercial, residential and other settings.

 

The 12 month agreement with the lighting company is expected to be followed either by further development work or by proceeding to product launch. The financial details of the agreement are not being disclosed.

 

 

Michael Edelman, Nanoco's Chief Executive Officer, said: "I'm delighted to sign this agreement with one of the world's largest lighting companies. We believe that our technology has the potential to unlock the widespread use of LED lighting in offices, homes and elsewhere because we can deliver the required colour performance."

 

 

 

 

For further information please contact:

 

Nanoco

Tel: +44 (0) 161 603 7900

Michael Edelman, Chief Executive Officer

Colin White, Chief Financial Officer

Bank of America Merrill Lynch - Corporate Broker

Tel: + 44 (0) 20 7996 2490

Will Smith

Canaccord Genuity - Nomad and Joint Broker

Tel: +44 (0) 20 7050 6500

Simon Bridges

Cameron Duncan

Buchanan Communications

Tel: +44 (0) 20 7466 5000

Mark Court / Christian Goodbody

 

 

Notes for editors:

 

About Nanoco Group plc

Nanoco is a world leader in the development and manufacture of commercial quantities of quantum dots for use in multiple applications including lighting, solar cells and biological imaging. Nanoco's quantum dots, which are free of heavy metals and comply with RoHS legislation, can be combined into a wide range of materials including liquids, polymers and glass. Nanoco forms strategic partnerships with major end users across a range of applications.

Nanoco was founded in 2001 and is based in Manchester, UK. Nanoco began trading on the AIM market of the London Stock Exchange in May 2009 under the ticker symbol NANO.

For further information, please visit www.nanocotechnologies.com.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSFAFIFFFSEDA
Date   Source Headline
26th Oct 20222:31 pmRNSLitigation Update – Funded Law Suit Filed in China
20th Oct 20227:00 amRNSPreliminary Results
14th Oct 202212:59 pmRNSPresentation via Investor Meet Company
14th Oct 202210:41 amRNSNotice of Results
28th Sep 20227:00 amRNSLitigation Update – Further Revised Trial Date
12th Sep 20228:25 amRNSTrading Update & Directorate Change
7th Sep 20223:47 pmRNSLitigation Update – Revised Trial Date
1st Sep 202210:22 amRNSDirector/PDMR Shareholding
31st Aug 20227:00 amRNSTwo Grant Funding Awards
30th Aug 20223:33 pmRNSHolding(s) in Company
30th Aug 20223:28 pmRNSDirector/PDMR Shareholding
25th Aug 20221:36 pmRNSDirector/PDMR Shareholding
23rd Aug 20222:22 pmRNSFunded Law Suit Filed in Germany
19th Aug 20228:21 amRNSLitigation Update – Pre-Trial Conference
18th Aug 20224:10 pmRNSDirector/PDMR Shareholding
16th Aug 20227:00 amRNSTrading Update
28th Jul 202210:42 amRNSHolding(s) in Company
13th Jul 20222:03 pmRNSReplacement - Director/PDMR Shareholding
13th Jul 202212:00 pmRNSHolding(s) in Company
13th Jul 202212:00 pmRNSDirector/PDMR Shareholding
13th Jul 202212:00 pmRNSHolding(s) in Company
30th Jun 20227:00 amRNSTotal Voting Rights
29th Jun 20227:00 amRNSChange of Auditor
23rd Jun 20223:48 pmRNSDirector/PDMR Shareholding
22nd Jun 20222:25 pmRNSHolding(s) in Company
21st Jun 20223:36 pmRNSDirector/PDMR Shareholding
21st Jun 20229:06 amRNSReplacement: Director/PDMR Shareholding
21st Jun 20227:00 amRNSDirector/PDMR Shareholding
17th Jun 20224:36 pmRNSPrice Monitoring Extension
17th Jun 202210:45 amRNSHolding(s) in Company
14th Jun 20229:42 amRNSHolding(s) in Company
9th Jun 20227:00 amRNSBlock listing Six-monthly Return
8th Jun 202212:00 pmRNSResults of Fundraise
8th Jun 20227:00 amRNSFundraise significantly over-subscribed
7th Jun 20225:16 pmRNSReplacement: Litigation Update
7th Jun 20224:55 pmRNSLitigation Update
6th Jun 20227:02 amRNSTrading Update & Proposed Fundraise
6th Jun 20227:00 amRNSMajor Work Package for European Customer
23rd May 20225:00 pmRNSHolding(s) in Company
17th May 20227:02 amRNSLitigation Update
13th May 202212:15 pmRNSHolding(s) in Company
13th Apr 20222:49 pmRNSHolding(s) in Company
12th Apr 20227:00 amRNSInterim Results
17th Mar 20227:00 amRNSAdditional Work Package for European Customer
15th Mar 20227:00 amRNSNotice of Interim Results
4th Feb 20223:14 pmRNSHolding(s) in Company
31st Jan 20227:00 amRNSTotal Voting Rights
9th Dec 20217:00 amRNSBlock listing Six-Monthly Return
2nd Dec 20217:18 amRNSBlock Listing Application
1st Dec 202112:30 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.